Pacific Biosciences of California, Inc. Forecast, price target & analysts
Pacific Biosciences of California, Inc. Target price 2025 - Analyst rating & recommendation
Pacific Biosciences of California, Inc. Classifications & Recommendation:
Pacific Biosciences of California, Inc. Price Target
| Target Price | $2.15 |
| Price | $1.36 |
| Potential |
57.78%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Pacific Biosciences of California, Inc. 2026 .
The average Pacific Biosciences of California, Inc. target price is $2.15.
This is
57.78%
register free of charge
$3.50
157.35%
register free of charge
$1.00
26.47%
register free of charge
|
|
| A rating was issued by 15 analysts: 6 Analysts recommend Pacific Biosciences of California, Inc. to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pacific Biosciences of California, Inc. stock has an average upside potential 2026 of
57.78%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 154.01 | 160.68 |
| 23.19% | 4.33% | |
| EBITDA Margin | -137.72% | -117.18% |
| 0.55% | 14.91% | |
| Net Margin | -303.96% | -134.03% |
| 71.09% | 55.91% |
14 Analysts have issued a sales forecast Pacific Biosciences of California, Inc. 2025 . The average Pacific Biosciences of California, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Pacific Biosciences of California, Inc. EBITDA forecast 2025. The average Pacific Biosciences of California, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Pacific Biosciences of California, Inc. Analysts have issued a net profit forecast 2025. The average Pacific Biosciences of California, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.59 | -0.73 |
| 31.40% | 54.09% | |
| P/E | negative | |
| EV/Sales | 4.29 |
14 Analysts have issued a Pacific Biosciences of California, Inc. forecast for earnings per share. The average Pacific Biosciences of California, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Pacific Biosciences of California, Inc....
Current Pacific Biosciences of California, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Apr 10 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jan 23 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
